Intravenous immunoglobulin therapy for COVID-19 ARDS.
| Autor: | Wilfong EM; Division of Rheumatology and Immunology and Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: erin.m.wilfong@vumc.org., Matthay MA; Department of Medicine and Department of Anesthesia, Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Lancet. Respiratory medicine [Lancet Respir Med] 2022 Feb; Vol. 10 (2), pp. 123-125. Date of Electronic Publication: 2021 Nov 11. |
| DOI: | 10.1016/S2213-2600(21)00450-1 |
| Abstrakt: | Competing Interests: EMW reports support from the National Institutes of Health (NIH); and reports research funding and consulting fees from Boehringer-Ingelheim, outside of the submitted work. MAM reports funding from the NIH, outside the submitted work; and consulting fees from Citrus Pharmaceuticals, outside the submitted work. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|